Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow RLYB
Rallybio Corporation (RLYB) Altman Z-score
Rallybio Corporation's Altman Z-score for fiscal 2025 is −3.12, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −3.12 | 0.85 |
| FY2024 | −3.97 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.92 | — | 1.10 | |
| Retained earnings / total assets | (4.85) | — | −6.79 | |
| EBIT / total assets | (0.53) | — | −1.75 | |
| Market value of equity / total liabilities | 7.18 | — | 4.31 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Distress zone | −3.12 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | 0.76 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ICCC ImmuCell Corporation compare | 2.8× |
| CLLS Cellectis S.A. compare | 0.0× |
| VXRT VAXART, INC. compare | −1.1× |
| RLYB Rallybio Corporation | −3.1× |
| MIST Milestone Pharmaceuticals Inc. compare | −4.6× |
| EQ Equillium, Inc. compare | −6.8× |
| ATRA Atara Biotherapeutics, Inc. compare | −126× |
| OKUR OnKure Therapeutics, Inc. compare | — |
| NMRA Neumora Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets